CCL20及DCs在慢性阻塞性肺疾病患者诱导痰中的变化及意义

Composite resin Curing Microleakage Time Cavity

目的检测慢性阻塞性肺疾病（COPD）患者诱导痰中CC亚族趋化因子配体20（CCL20）的含量,分析CCL20在COPD发病机制中的作用。方法以COPD患者为研究对象,并以无COPD者健康人作为对照,采用沙丁胺醇加高渗盐水超声雾化吸入方法诱导排痰,ELISA法检测CCL20的含量;同时,常规方法测定肺功能FEV1%及FEV1/FVC值。结果 CCL20在COPD分期的GOLDⅠ级、GOLDⅡ级以及GOLDⅢ~Ⅳ级均高于正常对照组和吸烟无COPD组,且差异有显著统计学意义（P〈0.01）。CCL20与COPD患者FEV1%之间呈负相关关系（P〈0.01）。结论 COPD患者CCL20含量显著升高,且与病情的严重程度明显相关,提示CCL20可能参与了COPD的炎症反应过程。

Objective To investigated CC chemokine ligand 20（CCL20） in the pathogensis of chronic obstructive pulmonary disease（COPD） through the change of CCL20 in the induced sputum of patients with COPD.Methods CCL20 were analyzed with ELISA in the sputum collected from COPD groups,cigarette smoke groups and control groups.FEV1% and FEV1/FVC were determined.ResultsCCL20 in the GOLD I～IV of COPD groups showed the upregulation of CCL20,compared with CCL20 in cigarette smoke groups and control groups.There was negative correlation between CCL20 and FEV1%（r=-0.913,P〈0.01）.Conclusion The significantly upregulation of CCL20 in the patients with COPD and the positive correlation between CCL20 and the stage of COPD show that CCL20 maybe contribute to the inflammatory reaction of COPD.